Manhattan Scientifics Receives Important Fuel Cell Patent

NEW YORK, Dec 16, 2004 /PRNewswire-FirstCall

Manhattan Scientifics, Inc. (OTC Bulletin Board: MHTX) confirmed today that it has been issued U.S. Patent No. 6,808,834 Koschany -- Fuel Cell Stack With Cooling Fins and Use of Expanded Graphite in Fuel Cells.

Marvin Maslow, CEO of Manhattan Scientifics, said, "As our economy actively begins to enter the fuel cell era, this patent on our NovArs fuel cell is potentially quite valuable for our company and our shareholders. Invented by Dr. Arthur Koschany, the NovArs fuel cell has been successfully demonstrated in a number of prototype pre-commercial situations. Smaller than a brick and weighing less than two pounds, the hydrogen-powered NovArs fuel cell is intended to power a bicycle or a motor scooter for several hundred miles without having to refuel depending on type of use, weight of rider, road conditions and the size of the fuel tank. Manhattan's early prototype vehicles have already demonstrated approximately 100-mile drive ranges."

"We are currently aggressively pursuing our business plan to have the NovArs fuel cell manufactured for use on electric bicycles and scooters in Asia. We have continuing initiatives in a number of other areas. We have raised a modest amount of capital and we are current in all of our SEC filings. We will keep investors apprised of material developments as they occur," Maslow said.

About Manhattan Scientifics

Manhattan Scientifics, Inc. ( http://www.mhtx.com ) is a technology development company working in the fields of alternative energy, fuel cell technologies and computer haptics technology. The company's facilities are located in Los Alamos and Albuquerque, N.M., and in New York City. Copies of Manhattan Scientifics' press releases, current quotes, stock charts and other information for investors may be found on the websites http://www.hawkassociates.com and http://www.hawkmicrocaps.com .

The foregoing press release contains forward-looking statements (including expectation of future events), which are subject to risks and uncertainty, which may be beyond the company's control. Actual results could differ materially for many reasons including but not limited to completion of R&D and successful commercialization of products/services, patent completion, and prosecution and defense against well-capitalized competitors. These are serious risks and there is no assurance that our forward-looking statements will occur or prove to be accurate.

SOURCE Manhattan Scientifics

News Provided By